The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The fund will take equity positions in India-focused healthcare and life sciences-related companies
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
MedisimVR is a VR based medical education platform for doctors, nurses & allied health professionals. It aims to make comprehensive Virtual Reality medical simulation more accessible and affordable
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Subscribe To Our Newsletter & Stay Updated
